Lv1
60 积分 2022-05-09 加入
Ivonescimab and other anti-programmed death-1/ligand 1 (PD-(L)1)/vascular endothelial growth factor (VEGF) bispecific antibodies: progress and prospects in cancer therapy
2天前
已完结
Hy's law: predicting serious hepatotoxicity
24天前
已完结
Becotatug vedotin, MRG003, in previously treated recurrent or metastatic nasopharyngeal carcinoma: A multicenter, single-arm, phase IIa trial
1个月前
已完结
Camrelizumab Plus Apatinib and Temozolomide as First-Line Treatment in Patients With Advanced Acral Melanoma
1个月前
已完结
Toripalimab vs Dacarbazine as First-Line Therapy for Advanced Melanoma of Acral Subtype
1个月前
已完结
Baseline Serum neutrophil-to-lymphocyte ratio in acral melanoma compared with nonacral melanoma and its prognostic significance
4个月前
已完结
Comparative investigation of cell cycle and immunomodulatory genes in mucosal and cutaneous melanomas: Preliminary data suggest a potential promising clinical role for p16 and the PD-1/PD-L1 axis
4个月前
已关闭
Targeting Solid Tumors Using CD3 Bispecific Antibodies
5个月前
已完结
Hyperprogressive disease: recognizing a novel pattern to improve patient management
5个月前
已完结
Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma
5个月前
已完结
皖公网安备34019202002308
